Payload Information
General Information of This Payload
| Payload ID | PAY0CVJDO |
|||||
|---|---|---|---|---|---|---|
| Name | CD33-11A1-v1417 (C)-#39 Payload |
|||||
| Synonyms |
CD33-11A1-v1417 (C)-#39 Payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C39H39Cl2N4O8P |
|||||
| Isosmiles | CNCCN(C)C(OC1=CC2=C([C@@H](CN2C(C34CC35CC5(C(N6C[C@H](C7=C6C=C(OP(O)(O)=O)C8=CC=CC=C78)CCl)=O)C4)=O)CCl)C9=CC=CC=C91)=O |
|||||
| InChI |
InChI=1S/C39H39Cl2N4O8P/c1-42-11-12-43(2)36(48)52-30-13-28-32(26-9-5-3-7-24(26)30)22(15-40)17-44(28)34(46)37-19-38(21-39(37,38)20-37)35(47)45-18-23(16-41)33-27-10-6-4-8-25(27)31(14-29(33)45)53-54(49,50)51/h3-10,13-14,22-23,42H,11-12,15-21H2,1-2H3,(H2,49,50,51)/t22-,23-,37?,38?,39?/m1/s1
|
|||||
| InChIKey |
BGXPTLTVCACSPS-OJOJXYPESA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
793.641 |
Polar area |
148.95 |
||
Complexity |
2285.942689 |
xlogp Value |
6.323 |
|||
Heavy Count |
54 |
Rot Bonds |
10 |
|||
Hbond acc |
7 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
CD33-11A1-v1417 (C)-#39 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.85 ng/mL
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing NB4 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
|
||||
| In Vitro Model | Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA | NB4 cells | CVCL_0005 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.43 ng/mL
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing HL60 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
|
||||
| In Vitro Model | Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation | HL60 cells | CVCL_0002 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
14.17 ng/mL
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing HEL92.1.7 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
|
||||
| In Vitro Model | Acute erythroid leukemia, Erythroleukemia | HEL92.1.7 cells | CVCL_2481 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 1000 ng/mL | Negative CD33 expression (CD33-) | ||
| Method Description |
CD33-non-expressing Raji cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
CD33-11A1-v1417 (K334C)- (K392C)-#39 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.81 ng/mL
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing HL60 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 33 concentrations.
|
||||
| In Vitro Model | Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation | HL60 cells | CVCL_0002 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.98 ng/mL
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing NB4 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 33 concentrations.
|
||||
| In Vitro Model | Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA | NB4 cells | CVCL_0005 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
12.1 ng/mL
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing HEL92.1.7 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 33 concentrations.
|
||||
| In Vitro Model | Acute erythroid leukemia, Erythroleukemia | HEL92.1.7 cells | CVCL_2481 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 6323 ng/mL | Negative CD33 expression (CD33-) | ||
| Method Description |
CD33-non-expressing Raji cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 33 concentrations.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
CD33-11A1-v1417 (K290C)- (K334C)-#39 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
4.58 ng/mL
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing HL60 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 32 concentrations.
|
||||
| In Vitro Model | Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation | HL60 cells | CVCL_0002 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
5.21 ng/mL
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing NB4 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 32 concentrations.
|
||||
| In Vitro Model | Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA | NB4 cells | CVCL_0005 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
20.78 ng/mL
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing HEL92.1.7 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 32 concentrations.
|
||||
| In Vitro Model | Acute erythroid leukemia, Erythroleukemia | HEL92.1.7 cells | CVCL_2481 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 1000 ng/mL | Negative CD33 expression (CD33-) | ||
| Method Description |
CD33-non-expressing Raji cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 32 concentrations.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
References